Value proposition

Passion for Innovation. Compassion for Patients.

Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people around the world by leveraging our world-class science and technology.

In Europe, we want to become the benchmark for customer centricity in the areas we work in and a competitive player in Oncology. For these reasons we are constantly looking for new talents that are willing to deliver the best solutions to the various healthcare professionals who aim to provide their patients with the best possible therapy - whether in the cardiovascular or oncological field.

We know that our success in Europe relies on courageous people who seize opportunities and turn them into results. This is why we encourage our teams across Europe to be passionate about their objectives, challenge conventional thinking and share their local recipes for success and learnings with the whole company. It is only through their input, ideas and honest feedback that we can learn and leverage the full potential of our company.

In Europe we are operating in 13 countries. Because of our rather small size compared to larger pharmaceutical companies, each of our employees can have a huge impact – whether they work in the medical area, sales force, business intelligence or the IT department. This is why everybody at Daiichi Sankyo rolls up their sleeves and gets things done, even if this means that they sometimes have to go beyond their usual duties.

If you would like to be an active member of our European family, we highly appreciate your application. Please take a look at our current vacancies.

Imprint: https://www.daiichi-sankyo.eu/meta-navigation/imprint

All information posted by Daiichi Sankyo Europe on this channel is intended for non-US, non-Canada & non-UK visitors.

cardiovascular diseases, glucose metabolic disorders, infectious diseases, cancer / oncology, immunity and allergies, and bones/joint diseases, antibody drug conjugates, anticoagulation, and ADC